Trial Profile

A Multi-center, Prospective, Non-randomized, Open-label Study of the Efficacy and Safety of Osimertinib Combined with Aspirin in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Are T790M-positive and Resistant to First-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2025 Phase changed from IV to II. Trial design changed to parallel and open label.
27 Feb 2025 Status changed from not yet recruiting to completed.
22 Jul 2020 Planned initiation date changed from 1 Dec 2019 to 1 Aug 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com